BACKGROUND: Although dihydroartemisinin-piperaquine (DP) is used primarily in children, pharmacokinetic/pharmacodynamic (PK/PD) data on DP use in young children are lacking. METHODS: We conducted a prospective PK/PD study of piperaquine in 107 young children in Uganda. Samples were collected up to 28 days after 218 episodes of malaria treatment, which occurred during follow-up periods of up to 5 months. Malaria follow-up was conducted actively to day 28 and passively to day 63. RESULTS: The median capillary piperaquine concentration on day 7 after treatment was 41.9 ng/mL. Low piperaquine concentrations were associated with an increased risk of recurrent malaria for up to 42 days, primarily in those receiving trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis. In children not receiving TMP-SMX, low piperaquine concentrations were only modestly associated with an increased risk of recurrent malaria. However, for children receiving TMP-SMX, associations were strong and evident for all sampling days, with PQ concentrations of ≤ 27.3 ng/mL on day 7 associated with a greatly increased risk of recurrent malaria. Notably, of 132 cases of recurrent malaria, 119 had detectable piperaquine concentrations at the time of presentation with recurrent malaria. CONCLUSIONS: These piperaquine PK/PD data represent the first in children <2 years of age. Piperaquine exposure on day 7 correlated with an increased risk of recurrent malaria after DP treatment in children receiving TMP-SMX prophylaxis. Interestingly, despite strong associations, infants remained at risk for malaria, even if they had residual levels of piperaquine.
RCT Entities:
BACKGROUND: Although dihydroartemisinin-piperaquine (DP) is used primarily in children, pharmacokinetic/pharmacodynamic (PK/PD) data on DP use in young children are lacking. METHODS: We conducted a prospective PK/PD study of piperaquine in 107 young children in Uganda. Samples were collected up to 28 days after 218 episodes of malaria treatment, which occurred during follow-up periods of up to 5 months. Malaria follow-up was conducted actively to day 28 and passively to day 63. RESULTS: The median capillary piperaquine concentration on day 7 after treatment was 41.9 ng/mL. Low piperaquine concentrations were associated with an increased risk of recurrent malaria for up to 42 days, primarily in those receiving trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis. In children not receiving TMP-SMX, low piperaquine concentrations were only modestly associated with an increased risk of recurrent malaria. However, for children receiving TMP-SMX, associations were strong and evident for all sampling days, with PQ concentrations of ≤ 27.3 ng/mL on day 7 associated with a greatly increased risk of recurrent malaria. Notably, of 132 cases of recurrent malaria, 119 had detectable piperaquine concentrations at the time of presentation with recurrent malaria. CONCLUSIONS: These piperaquine PK/PD data represent the first in children <2 years of age. Piperaquine exposure on day 7 correlated with an increased risk of recurrent malaria after DP treatment in children receiving TMP-SMX prophylaxis. Interestingly, despite strong associations, infants remained at risk for malaria, even if they had residual levels of piperaquine.
Authors: Corine Karema; Caterina I Fanello; Chantal van Overmeir; Jean-Pierre van Geertruyden; Walli van Doren; Daniel Ngamije; Umberto D'Alessandro Journal: Trans R Soc Trop Med Hyg Date: 2006-06-12 Impact factor: 2.184
Authors: J Tarning; I Zongo; F A Somé; N Rouamba; S Parikh; P J Rosenthal; W Hanpithakpong; N Jongrak; N P J Day; N J White; F Nosten; J-B Ouedraogo; N Lindegardh Journal: Clin Pharmacol Ther Date: 2012-01-18 Impact factor: 6.875
Authors: J Tarning; E A Ashley; N Lindegardh; K Stepniewska; L Phaiphun; N P J Day; R McGready; M Ashton; F Nosten; N J White Journal: Antimicrob Agents Chemother Date: 2008-01-07 Impact factor: 5.191
Authors: R N Price; A R Hasugian; A Ratcliff; H Siswantoro; H L E Purba; E Kenangalem; N Lindegardh; P Penttinen; F Laihad; E P Ebsworth; N M Anstey; E Tjitra Journal: Antimicrob Agents Chemother Date: 2007-09-10 Impact factor: 5.191
Authors: Kimberly K Scarsi; Fatai A Fehintola; Qing Ma; Francesca T Aweeka; Kristin M Darin; Gene D Morse; Ibrahim Temitope Akinola; Waheed A Adedeji; Niklas Lindegardh; Joel Tarning; Oladosu Ojengbede; Isaac F Adewole; Babafemi Taiwo; Robert L Murphy; Olusegun O Akinyinka; Sunil Parikh Journal: J Antimicrob Chemother Date: 2014-01-19 Impact factor: 5.790
Authors: N C Sambol; L Yan; D J Creek; S A McCormack; E Arinaitwe; V Bigira; H Wanzira; A Kakuru; J W Tappero; N Lindegardh; J Tarning; F Nosten; F T Aweeka; S Parikh Journal: Clin Pharmacol Ther Date: 2015-05-02 Impact factor: 6.875
Authors: Moses R Kamya; James Kapisi; Victor Bigira; Tamara D Clark; Stephen Kinara; Florence Mwangwa; Mary K Muhindo; Abel Kakuru; Francesca T Aweeka; Liusheng Huang; Prasanna Jagannathan; Jane Achan; Diane V Havlir; Philip J Rosenthal; Grant Dorsey Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Issaka Zongo; Paul Milligan; Yves Daniel Compaore; A Fabrice Some; Brian Greenwood; Joel Tarning; Philip J Rosenthal; Colin Sutherland; Francois Nosten; Jean-Bosco Ouedraogo Journal: Antimicrob Agents Chemother Date: 2015-04-27 Impact factor: 5.191